Cocrystal Pharma’s Participation in the Noble Capital Markets C-Suite Interview Series is Now Available Online
June 09 2021 - 2:30PM
Cocrystal Pharma, Inc. (Nasdaq: COCP),
(“Cocrystal” or the “Company”), a clinical-stage biotechnology
company discovering and developing novel antiviral therapeutics
that target the replication machinery of influenza viruses, the
SARS-CoV-2 virus, hepatitis C viruses and noroviruses, announces
that management’s participation in the Noble Capital Markets
C-Suite Interview Series is now available online. During the
30-minute video interview hosted by Noble Capital Markets Senior
Equity Research Analyst Robert LeBoyer, Cocrystal discussed its
antiviral drug-discovery and development work and provided program
updates.
“Cocrystal utilizes a proprietary
structure-based technology platform to discover viral inhibitors
that address underserved medical needs in very large markets
including pandemics and widespread viral infections,” said Sam Lee,
Ph.D., interim co-CEO and President. “This powerful platform
differentiates Cocrystal’s approach and allows us to focus on three
important drug-discovery processes including improvements with in
vitro potency, broad-spectrum activity and drug-resistance profile.
It is very difficult to improve these critical processes with
traditional drug discovery tools.”
“We are aggressively moving forward our
antiviral programs with multiple upcoming milestones including
results from the proof-of-concept animal study with our norovirus
program expected later this month, the planned initiation of a
Phase 1 influenza A clinical study in the third quarter and
advancing our COVID-19 programs toward pre-IND status,” added James
Martin, interim co-CEO and CFO. “Given our cost-efficient structure
and financial resources, we believe we have sufficient capital to
fund current operations and planned program activities through
2024. The possibility of milestone payments under our Merck
collaboration would extend that cash runway. We do not expect to
raise additional capital in 2021 and for some time beyond.”
Cautionary Note Regarding Forward-Looking
Statements
This press release and the interview referenced
above contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, including
statements regarding the expected future success of our discovery
and development activities in addressing major global medical
concerns; the expected achievement of key milestones in our
antiviral programs and the anticipated timing of achieving such
milestones, including reporting results from the proof-of-concept
animal study in our norovirus program expected in June 2021, the
planned initiation of the influenza A Phase 1 study during the
third quarter of 2021, identifying another SARS-CoV-2 preclinical
lead for oral administration in 2021, and advancing the COVID-19
programs toward pre-IND status with potential to initiate clinical
testing in 2022; our expectations and estimates regarding the
future applications and effectiveness of, and the market
opportunities for, our product candidates; potential receipt of
milestone payments and royalties under the collaboration agreement
with Merck Sharp & Dohme Corp., our plans with respect to
future capital raising activities and expected liquidity . The
words "believe," "may," "estimate," "continue," "anticipate,"
"intend," "should," "plan," "could," "target," "potential," "is
likely," "will," "expect" and similar expressions, as they relate
to us, are intended to identify forward-looking statements. We have
based these forward-looking statements largely on our current
expectations and projections about future events. Some or all of
the events anticipated by these forward-looking statements may not
occur. Important factors that could cause actual results to differ
from those in the forward-looking statements include, but are not
limited to the risks arising from the impact of the COVID-19
pandemic on the national and global economy, on our collaboration
partners and on our Company, including supply chain disruptions and
our continued ability to proceed with our programs, our reliance on
Merck for further development in the influenza A/B program under
the collaboration agreement and Merck’s further research and
internal priorities, the results of future preclinical and clinical
studies, general risks arising from clinical trials, receipt of
regulatory approvals, regulatory changes, and development of
effective treatments and/or vaccines by competitors, including as
part of the programs financed by the U.S. government. Further
information on our risk factors is contained in our filings with
the SEC, including our Annual Report on Form 10-K for the year
ended December 31, 2020. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor Contact:LHA Investor RelationsJody
Cain310-691-7100jcain@lhai.com
# # #
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024